PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17404023-7 2007 In addition, 10 uM celecoxib inhibited cell invasion/migration through the type I collagen matrix by approximately 40% within 24 h. The results of zymography reveal that, in the presence of 10 muL celecoxib, both MMP-2 and MMP-9 enzyme activity decreased by approximately 30-40%. Celecoxib 19-28 matrix metallopeptidase 9 Homo sapiens 223-228 19715751-8 2009 Our results showed that TPA-induced MMP-9 expression was inhibited by celecoxib in a dose-dependent fashion, but not MMP-1-expression. Celecoxib 70-79 matrix metallopeptidase 9 Homo sapiens 36-41 26592832-5 2015 Western blot analysis was used to detect the protein expression of RECK, matrix metalloproteinase (MMP)-2 and MMP-9 in celecoxib-treated MG-63 cells. Celecoxib 119-128 matrix metallopeptidase 9 Homo sapiens 110-115 26592832-10 2015 Western blot analyses revealed that the expression of MMP-2 and MMP-9 was markedly down-regulated but RECK, an inhibitor of MMPs, was markedly up-regulated in MG-63 cells exposed to 20 microg/ml celecoxib for 24 or 48h. Celecoxib 195-204 matrix metallopeptidase 9 Homo sapiens 64-69 26592832-13 2015 Celecoxib-induced down-regulation of MMP-2 and MMP-9 and up-regulation of RECK may contribute to the apoptosis induction and an alteration in local tumor microenvironment. Celecoxib 0-9 matrix metallopeptidase 9 Homo sapiens 47-52 26592832-14 2015 These findings suggest that celecoxib may exert at least in part of its anticancer effects via up-regulation of RECK to inhibit the expression of MMP-2 and MMP-9. Celecoxib 28-37 matrix metallopeptidase 9 Homo sapiens 156-161 24721459-8 2014 RESULTS: The presence of celecoxib normalized the release of PGE2 and diminished the CTS-induced COX-2, MMP-1, MMP-3, MMP-9 and ADAMTS-5 gene expressions while recovered the downregulated type II collagen and aggrecan gene expressions. Celecoxib 25-34 matrix metallopeptidase 9 Homo sapiens 118-123 24640603-10 2014 These data demonstrated that celecoxib-induced suppression of MMP-2 and MMP-9 activity might be involved in the inhibition of nasopharyngeal carcinoma cell lines invasion and migration. Celecoxib 29-38 matrix metallopeptidase 9 Homo sapiens 72-77 18303430-0 2008 Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. Celecoxib 30-39 matrix metallopeptidase 9 Homo sapiens 126-152 17404023-7 2007 In addition, 10 uM celecoxib inhibited cell invasion/migration through the type I collagen matrix by approximately 40% within 24 h. The results of zymography reveal that, in the presence of 10 muL celecoxib, both MMP-2 and MMP-9 enzyme activity decreased by approximately 30-40%. Celecoxib 197-206 matrix metallopeptidase 9 Homo sapiens 223-228 17313803-8 2006 The grey level of MMP-2 and MMP-9 in the combination and celecoxib groups were (99 +/- 20, 89 +/- 13) and (260 +/- 15, 180 +/- 13) respectively, both significantly lower than that of the control group [(314 +/- 11, 241 +/- 12), P < 0.05]. Celecoxib 57-66 matrix metallopeptidase 9 Homo sapiens 28-33 15256475-0 2004 Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Celecoxib 33-42 matrix metallopeptidase 9 Homo sapiens 261-287 16190383-5 2005 Celecoxib reduced IL-6 and MMP-9 secretion level of monocytes from ACS patients up to 48% and 50% respectively (all P < 0.05), in a concentration-dependent manner. Celecoxib 0-9 matrix metallopeptidase 9 Homo sapiens 27-32 16253161-9 2005 (4) The amount of MMP-2, MMP-9 produced by synovial fibroblasts under 12 h hypoxic condition was upregulated compared with that under normoxia or in response to celecoxib combined with hypoxia. Celecoxib 161-170 matrix metallopeptidase 9 Homo sapiens 25-30 35386439-5 2022 To solve these issues, a glucose and MMP-9 dual-response temperature-sensitive shape self-adaptive hydrogel (CBP/GMs@Cel&INS) was designed and constructed with polyvinyl alcohol (PVA) and chitosan grafted with phenylboric acid (CS-BA) by encapsulating insulin (INS) and gelatin microspheres containing celecoxib (GMs@Cel). Celecoxib 302-311 matrix metallopeptidase 9 Homo sapiens 37-42 35386439-6 2022 Temperature-sensitive self-adaptive CBP/GMs@Cel&INS provides a new way to balance the fluid-like mobility (self-adapt to deep wounds quickly, approximately 37 C) and solid-like elasticity (protect wounds against external forces, approximately 25 C) of self-adaptive hydrogels, while simultaneously releasing insulin and celecoxib on-demand in the environment of high-level glucose and MMP-9. Celecoxib 322-331 matrix metallopeptidase 9 Homo sapiens 387-392 32994805-8 2020 In addition, celecoxib alone or in combination with aspirin inhibited the migration and invasion of NSCLC cells by inhibiting MMP-9 and MMP-2 activity levels. Celecoxib 13-22 matrix metallopeptidase 9 Homo sapiens 126-131 33194674-9 2020 Unlike suprapharmacological dose, metronomic Celecoxib can only inhibit HCC cell invasion after a 7-day course of treatment via NF-kappaB/MMP9 dependent, COX2/PGE2 independent pathway. Celecoxib 45-54 matrix metallopeptidase 9 Homo sapiens 138-142 33019464-4 2020 CONCLUSION: Celecoxib mainly regulates the proliferation, migration, and invasion of tumor cells by inhibiting the cyclooxygenases-2/prostaglandin E2 signal axis and thereby inhibiting the phosphorylation of nuclear factor-kappa-gene binding, Akt, signal transducer and activator of transcription and the expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. Celecoxib 12-21 matrix metallopeptidase 9 Homo sapiens 350-376 31629465-2 2020 Similar to celecoxib, this compound could also inhibit matrix metalloproteinase (MMP)-9 activity. Celecoxib 11-20 matrix metallopeptidase 9 Homo sapiens 55-87 32792943-10 2020 In addition, either celecoxib alone or in combination with metformin suppressed NSCLC cell migration and invasion by inhibiting FAK, N-cadherin, and matrix metalloproteinase-9 activities. Celecoxib 20-29 matrix metallopeptidase 9 Homo sapiens 149-175 27430377-8 2016 Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells. Celecoxib 0-9 matrix metallopeptidase 9 Homo sapiens 80-85 29383179-6 2017 Additionally, either celecoxib alone or in combination with curcumol inhibited NSCLC cell migration and invasion by suppressing FAK and matrix metalloproteinase-9 activities. Celecoxib 21-30 matrix metallopeptidase 9 Homo sapiens 136-162